Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.

Thi Truc Anh NguyenLauren M PostlewaitChao ZhangJane L MeiselRuth O'ReganSunil BadveKevin KalinskyXiaoxian Li

Published in: Breast cancer research and treatment (2022)

This study demonstrates that the metastatic rate of T1a and T1b ER+/HER2-/LN- breast cancer is very low. Patients with low grade (1 or 2), T1a ER+/HER2-/LN- breast cancer may not need RS for treatment decision-making; however, in patients with high-grade T1a or T1b ER+/HER2-/LN- breast cancer, RS analysis should be strongly considered.

Keyphrases

estrogen receptor
low grade
high grade
lymph node
decision making
small cell lung cancer
squamous cell carcinoma
endoplasmic reticulum
early stage
smoking cessation
replacement therapy